PolyPid (PYPD) EPS (Basic) Growth (3y) (2022 - 2026)
PolyPid (PYPD) EPS (Basic) Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | -38.31% |
| 10 | PolyPid | 112.74 Mn | 105.97 Mn | - | 4,989.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,255.72% |
| Mar 31, 2026 | -65.25% |
| Dec 31, 2025 | -62.83% |
| Sep 30, 2025 | -70.21% |
| Jun 30, 2025 | 9,256.92% |
| Mar 31, 2025 | -66.56% |
| Dec 31, 2024 | -59.47% |
| Sep 30, 2024 | -57.57% |
| Jun 30, 2024 | -99.75% |
| Mar 31, 2024 | -53.90% |
| Dec 31, 2023 | -42.42% |
| Sep 30, 2023 | -31.61% |
| Jun 30, 2023 | -99.85% |
| Dec 31, 2022 | -63.40% |
| Jun 30, 2022 | -99.61% |